These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 23896958)

  • 41. Multi-psychotropic drug prescription and the association to neuropsychiatric symptoms in three Norwegian nursing home cohorts between 2004 and 2011.
    Gulla C; Selbaek G; Flo E; Kjome R; Kirkevold Ø; Husebo BS
    BMC Geriatr; 2016 Jun; 16():115. PubMed ID: 27245665
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience.
    Kindermann SS; Dolder CR; Bailey A; Katz IR; Jeste DV
    Drugs Aging; 2002; 19(4):257-76. PubMed ID: 12038878
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antidepressants for agitation and psychosis in dementia.
    Seitz DP; Adunuri N; Gill SS; Gruneir A; Herrmann N; Rochon P
    Cochrane Database Syst Rev; 2011 Feb; (2):CD008191. PubMed ID: 21328305
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Modifiable factors related to abusive behaviors in nursing home residents with dementia.
    Volicer L; Van der Steen JT; Frijters DH
    J Am Med Dir Assoc; 2009 Nov; 10(9):617-22. PubMed ID: 19883883
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease.
    Clark WS; Street JS; Feldman PD; Breier A
    J Clin Psychiatry; 2001 Jan; 62(1):34-40. PubMed ID: 11235926
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial.
    Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Greenspan A
    Int J Geriatr Psychiatry; 2005 Dec; 20(12):1153-7. PubMed ID: 16315159
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer's disease: prospective analyses from the Predictors Study.
    Stern Y; Albert M; Brandt J; Jacobs DM; Tang MX; Marder K; Bell K; Sano M; Devanand DP; Bylsma F
    Neurology; 1994 Dec; 44(12):2300-7. PubMed ID: 7991116
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The use of antipsychotics is associated with lower mortality in patients with Alzheimer's disease: A nationwide population-based nested case-control study in Taiwan.
    Chu CS; Li WR; Huang KL; Su PY; Lin CH; Lan TH
    J Psychopharmacol; 2018 Nov; 32(11):1182-1190. PubMed ID: 29926765
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sex Differences in Antipsychotic and Benzodiazepine Prescribing Patterns: A Cohort Study of Newly Admitted Nursing Home Residents with Dementia in Ontario, Canada.
    Maclagan LC; Maxwell CJ; Harris DA; Campitelli MA; Diong C; Lapane KL; Hogan DB; Rochon P; Herrmann N; Bronskill SE
    Drugs Aging; 2020 Nov; 37(11):817-827. PubMed ID: 32978758
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Psychosocial or clinico-demographic factors related to neuropsychiatric symptoms in patients with Alzheimer's disease needing interventional treatment: analysis of the CATIE-AD study.
    Nagata T; Nakajima S; Shinagawa S; Plitman E; Graff-Guerrero A; Mimura M; Nakayama K
    Int J Geriatr Psychiatry; 2017 Dec; 32(12):1264-1271. PubMed ID: 27714849
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Psychiatric symptoms vary with the severity of dementia in probable Alzheimer's disease.
    Lopez OL; Becker JT; Sweet RA; Klunk W; Kaufer DI; Saxton J; Habeych M; DeKosky ST
    J Neuropsychiatry Clin Neurosci; 2003; 15(3):346-53. PubMed ID: 12928511
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia.
    Pollock BG; Mulsant BH; Rosen J; Mazumdar S; Blakesley RE; Houck PR; Huber KA
    Am J Geriatr Psychiatry; 2007 Nov; 15(11):942-52. PubMed ID: 17846102
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Longitudinal outcome of Parkinson's disease patients with psychosis.
    Factor SA; Feustel PJ; Friedman JH; Comella CL; Goetz CG; Kurlan R; Parsa M; Pfeiffer R;
    Neurology; 2003 Jun; 60(11):1756-61. PubMed ID: 12796526
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lithium Treatment for Agitation in Alzheimer's disease (Lit-AD): Clinical rationale and study design.
    Devanand DP; Strickler JG; Huey ED; Crocco E; Forester BP; Husain MM; Vahia IV; Andrews H; Wall MM; Pelton GH
    Contemp Clin Trials; 2018 Aug; 71():33-39. PubMed ID: 29859917
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antipsychotic use and the risk of diabetes in nursing home residents with dementia.
    Jalbert JJ; Daiello LA; Eaton CB; Miller SC; Lapane KL
    Am J Geriatr Pharmacother; 2011 Jun; 9(3):153-63. PubMed ID: 21596626
    [TBL] [Abstract][Full Text] [Related]  

  • 56. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology.
    Schneider LS; Tariot PN; Lyketsos CG; Dagerman KS; Davis KL; Davis S; Hsiao JK; Jeste DV; Katz IR; Olin JT; Pollock BG; Rabins PV; Rosenheck RA; Small GW; Lebowitz B; Lieberman JA
    Am J Geriatr Psychiatry; 2001; 9(4):346-60. PubMed ID: 11739062
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics.
    Liperoti R; Gambassi G; Lapane KL; Chiang C; Pedone C; Mor V; Bernabei R
    J Clin Psychiatry; 2005 Sep; 66(9):1090-6. PubMed ID: 16187764
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and Safety of Citalopram Compared to Atypical Antipsychotics on Agitation in Nursing Home Residents With Alzheimer Dementia.
    Viscogliosi G; Chiriac IM; Ettorre E
    J Am Med Dir Assoc; 2017 Sep; 18(9):799-802. PubMed ID: 28739492
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Baseline Predictors of Antipsychotic Treatment Continuation and Response at Week 8 in Patients with Alzheimer's Disease with Psychosis or Aggressive Symptoms: An Analysis of the CATIE-AD Study.
    Nagata T; Nakajima S; Shinagawa S; Plitman E; Nakayama K; Graff-Guerrero A; Mimura M
    J Alzheimers Dis; 2017; 60(1):263-272. PubMed ID: 28800334
    [TBL] [Abstract][Full Text] [Related]  

  • 60. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness- Alzheimer's Disease (CATIE-AD): baseline characteristics.
    Ismail MS; Dagerman K; Tariot PN; Abbott S; Kavanagh S; Schneider LS
    Curr Alzheimer Res; 2007 Jul; 4(3):325-35. PubMed ID: 17627490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.